Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
Cochrane Database of Systematic Reviews, 2007•cochranelibrary.com
Background Cytomegalovirus (CMV) is the most common virus causing disease and death
in solid organ transplant recipients during the first six months post‐transplant. Previous
systematic reviews have demonstrated the efficacy of antiviral medications used
prophylactically or pre‐emptively in preventing CMV disease. In this review the efficacy of
older agents (immunoglobulins (IgG), anti CMV vaccines and interferon) are examined.
Objectives To assess the benefits and harms of IgG, anti CMV vaccines or interferon for …
in solid organ transplant recipients during the first six months post‐transplant. Previous
systematic reviews have demonstrated the efficacy of antiviral medications used
prophylactically or pre‐emptively in preventing CMV disease. In this review the efficacy of
older agents (immunoglobulins (IgG), anti CMV vaccines and interferon) are examined.
Objectives To assess the benefits and harms of IgG, anti CMV vaccines or interferon for …
Background
Cytomegalovirus (CMV) is the most common virus causing disease and death in solid organ transplant recipients during the first six months post‐transplant. Previous systematic reviews have demonstrated the efficacy of antiviral medications used prophylactically or pre‐emptively in preventing CMV disease. In this review the efficacy of older agents (immunoglobulins (IgG), anti CMV vaccines and interferon) are examined.
Objectives
To assess the benefits and harms of IgG, anti CMV vaccines or interferon for preventing symptomatic CMV disease in solid organ transplant recipients.
cochranelibrary.com